Core Viewpoint - Worldline successfully completed a share capital increase of approximately €392 million as part of a larger €500 million capital raise aimed at strengthening its financial structure and supporting its strategic goals for growth and cash flow generation [1][3]. Summary by Sections Capital Increase Details - The gross proceeds from the Rights Issue amounted to €391,780,753.76, achieved through the issuance of 1,939,508,682 new shares at a subscription price of €0.202 per share, with a subscription ratio of six new shares for one existing share [2]. - The Rights Issue was oversubscribed, with total investor demand reaching approximately €473 million and a subscription rate of about 121% [3]. Strategic Investors Participation - Strategic investors, including Bpifrance Participations, Crédit Agricole S.A., and BNP Paribas, subscribed to the Rights Issue for a total of approximately €135 million on a pro rata basis, with an additional amount of €29 million subject to reduction [5]. - Banque Fédérative du Crédit Mutuel acquired preferential subscription rights from SIX Group AG and exercised these rights for 179,121,174 new shares [6]. Allocation of New Shares - A total of 1,858,374,426 new shares were subscribed without reduction, representing approximately 96% of the new shares to be issued, while orders subject to reduction accounted for 481,368,553 new shares, with only 81,134,256 new shares allocated based on a calculated allotment coefficient [7]. - Specific subscriptions included Bpifrance Participations with 201,869,552 new shares for €41 million, Crédit Agricole S.A. with 200,019,952 new shares for €40 million, and BNP Paribas with 166,885,098 new shares for €34 million [8][12]. Impact on Share Capital - Following the settlement and delivery of the new shares, Worldline's share capital will increase to €45,255,202.58, divided into 2,262,760,129 ordinary shares with a nominal value of €0.02 each [9].

Core Viewpoint - Worldline S.A. is initiating a reserved capital increase of approximately €108 million, marking the first phase of a larger planned capital increase of around €500 million to strengthen its financial structure and support its North Star 2030 transformation plan [1][4][23]. Group 1: Capital Increase Details - The board of directors approved the issuance of 39,287,272 new ordinary shares at a price of €2.75 per share, which will be subscribed by strategic investors including Bpifrance Participations, Crédit Agricole S.A., and BNP Paribas [2][9]. - The total gross amount from the reserved capital increase is approximately €108 million, which will be utilized for the execution of the North Star 2030 transformation plan and to enhance the company's financial flexibility [4][8]. - Following the reserved capital increase, the share capital will increase to €6,465,028.94, divided into 323,251,447 fully subscribed and paid-up ordinary shares [4][20]. Group 2: Strategic Investors' Commitments - Bpifrance Participations will subscribe for approximately €46 million, Crédit Agricole S.A. for about €30 million, and BNP Paribas for around €32 million, resulting in respective ownership stakes of 9.6%, 9.5%, and 7.9% post-increase [3][20]. - The strategic investors have committed to subscribe up to €135 million in the upcoming rights issue, which will be open to all shareholders [5][22]. - A standby underwriting commitment of approximately €257 million has been provided by four financial institutions to support the rights issue [6]. Group 3: Timeline and Execution - The settlement of the reserved capital increase is scheduled for March 10, 2026, with the new shares expected to be admitted to trading on Euronext Paris on the same date [4][16]. - The rights issue is anticipated to be launched in March 2026, subject to market conditions and regulatory approval [7][8]. Group 4: Shareholding Structure Impact - Prior to the reserved capital increase, the company's share capital was €5,679,283.50, divided into 283,964,175 shares, with a significant portion held by free float [18][20]. - Post-increase, the shareholding structure will reflect the new stakes of the strategic investors, enhancing their influence within the company [20][23].

Core Points - Theon International Plc is launching a rights offering to raise approximately €150 million through the issuance of 8,624,645 new ordinary shares at a subscription price of €17.40 per share, which represents a discount of 30.8% to the theoretical ex-rights price [3][4][10] - The majority shareholders, Venetus Limited and CHRE Investments Limited, have committed to subscribe for approximately €107 million of new shares, representing about 71.0% of the offering [5][6] - The proceeds from the rights offering are intended to partially finance the acquisition of a 9.8% stake in Exosens SA for €268.7 million, positioning Theon as the second-largest shareholder in Exosens [6][8][7] Offering Details - The rights offering will allow existing shareholders to receive 1 right per ordinary share held as of the record date, with 8 rights required to subscribe for 1 new share [4][9] - The subscription period will run from December 2, 2025, to December 15, 2025, with rights trading occurring from December 2 to December 11, 2025 [12][13] - Any unsubscribed shares will be offered to eligible institutional investors through private placements [15] Financial Context - The subscription price of €17.40 per share is based on a closing price of €26.10 per ordinary share, indicating a significant discount [10] - The expected net proceeds from the offering are approximately €146 million, which will be utilized for the Exosens acquisition [8] Company Background - Theon Group specializes in developing and manufacturing advanced night vision and thermal imaging systems for defense and security applications, with a global presence [34] - The company has been listed on Euronext Amsterdam since February 2024 and has over 240,000 systems in service across 71 countries, including 26 NATO member countries [34]

Share capital increase reserved for employees “Elis for All 2025” Saint-Cloud, 13 November 2025 The subscription period for the share capital increase reserved for Elis employees ended on 2 October 2025. 5.8% of employees in 20 countries chose to participate, either directly or via the Elis Group employee shareholding fund, in this operation, for a total subscription of nearly 15 million euros. Implemented by the Elis Supervisory Board on December 17, 2024 and by the Management Board on July 31, 2025, on th ...

Core Points - The EfTEN Real Estate Fund AS shareholders authorized the Supervisory Board to increase the fund's share capital through public and/or private offerings, excluding pre-emptive subscription rights of existing shareholders for one year [1] - The fund plans to conduct a directed share issue to raise a total of 1.6 million euros, primarily from Lithuania, with a share price set at 19.11 euros per share based on the 60-day average closing price [2] - A total of 84,506 new shares will be issued at a nominal value of 10 euros per share, resulting in a new share capital of 115,248,460 euros, with proceeds intended to finance further investment activities [3]

Group 1 - The extraordinary general meeting of Havila Kystruten AS resolved to conduct a share consolidation in the ratio of 50:1 [1] - A share capital increase was approved to facilitate the share consolidation due to the current number of shares not being divisible by 50 [1] - Havila Holding AS, associated with primary insiders, subscribed for 41 shares in the share capital increase [2]

Core Points - The Board of Directors of Havila Kystruten AS has announced an extraordinary general meeting scheduled for November 7, 2025, at 10:00 CET [1] - The agenda includes the election of independent board members, a reverse share split in the ratio of 50:1, and a share capital increase to facilitate the share consolidation [2] - Shareholders with non-divisible shares will have their holdings rounded down, and fractional shares will be sold with proceeds donated to charity [3] - The meeting will be conducted digitally with electronic voting options available [4] Agenda Items - Election of Board members to ensure independence for potential refinancing [2] - Implementation of a reverse share split at a ratio of 50:1 [2] - Proposal for a share capital increase to support the share consolidation [2] - Authorization for the Board to set key dates related to the share consolidation and change of ISIN [2] Shareholder Information - Shareholders must hold a number of shares divisible by 50 to avoid rounding down [3] - Fractional shares will not be issued, and no compensation will be provided for rounding [3] - Proceeds from the sale of consolidated fractional shares will be donated to a charitable cause [3] Meeting Logistics - The extraordinary general meeting will be held as a digital meeting with electronic voting via Lumi [4] - Advance voting and proxy authorizations are permitted [4] - Relevant documents and meeting notice are available on the company's website [4]

Core Points - The Company announced the exercise of 19,470,726 Warrants, resulting in the subscription for the same number of new shares at an exercise price of NOK 1.00 each [1] - The Board of Directors has approved the allocation of new shares and resolved to increase the Company's share capital accordingly [2] - Following the registration of the share capital increase, the Company's total share capital will amount to NOK 429,142,639.50, divided into 858,285,279 shares with a nominal value of NOK 0.50 each [3] Company Overview - Ensurge Micropower is focused on developing ultrathin, flexible, reliable, and fundamentally safe solid-state lithium microbattery technology [3] - The Company operates with a team of forty specialists based in Silicon Valley, emphasizing innovation in microbattery technology suitable for various applications, including wearables and IoT devices [4] - Ensurge's manufacturing facility utilizes patented process technology and aims to scale production through partnerships with specialized industrial manufacturers [5] - The Company is listed on the Norwegian stock exchange and is supported by reputable financial investors, indicating a strong strategic investment and collaboration [6]

Core Points - Zealand Pharma A/S announced the total number of shares and voting rights as of September 30, 2025, following a share capital increase due to the exercise of employee warrants [1][2] - The total number of shares is 71,364,728, with a corresponding share capital of DKK 71,364,728 and the same number of voting rights [3] Company Overview - Zealand Pharma A/S is a biotechnology company focused on the discovery and development of innovative peptide-based medicines, with over 10 drug candidates in clinical development, including two that have reached the market and three in late-stage development [3] - The company was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States [4]

Group 1 - The company Kaldvik AS has resolved to settle a receivable of NOK 43,594,165 related to the acquisition of Mossi ehf. by issuing 1,579,498 new shares [1][2] - The new shares will be issued to Heimstø AS, which is associated with a primary insider of Kaldvik AS [2] - Following the share capital increase, the company's total share capital will amount to NOK 16,826,833.50, divided into 168,268,335 shares, each with a nominal value of NOK 0.10 [3] Group 2 - The company will register the new share capital increase with the Norwegian Register of Business Enterprises and will announce the completion of this registration [3] - This information is subject to the disclosure requirements of Regulation EU 596/2014 (MAR) and the Norwegian Securities Trading Act [4]